[
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "Ki",
        "value": "10 nM",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "Ki",
        "value": "2 nM",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "Ki",
        "value": "1 nM",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "40%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "50%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "α3 subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "60%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "αl subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "30%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "αl subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "20%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    },
    {
        "molecule_name": "compounds of the invention",
        "protein_target_name": "αl subunit of the human GABAA receptor",
        "binding_metric": "EC20",
        "value": "10%",
        "unit": "%",
        "is_logarithmic": false,
        "raw_mentions": "The α3 subunit binding affinity (Ki) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less. \nThe compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. \nThe compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the αl subunit of the human GABAA receptor."
    }
]